
https://www.science.org/content/blog-post/layoffs-more-layoffs
# Article Title (December 2008)

## 1. SUMMARY

The article reports on layoffs in the pharmaceutical and biotechnology sectors, focusing on two specific cases. Bristol-Myers Squibb is described as announcing research layoffs across its New Jersey and Connecticut sites, with the timing exacerbated by year-end accounting practices. Entremed is highlighted as undergoing a more severe cutback, with 60% of employees being let go, including the CEO and CFO, indicating a precarious situation for the company that had previously gained attention for Judah Folkman's anti-angiogenic peptide research.

The author expresses sympathy for affected employees, having experienced layoffs personally, and offers to help by listing companies that are hiring. The piece also mentions a reporter working on a "Careers in Pharma" story about chemistry layoffs, seeking input from affected individuals. The article captures the difficult employment climate in the pharmaceutical industry during late 2008.

## 2. HISTORY

**Bristol-Myers Squibb**: Following the 2008 layoffs, Bristol-Myers Squibb continued its strategic transformation toward biologics and specialty care. The company divested from traditional small-molecule pharmaceuticals and consumer health products while acquiring companies like Medarex (2009) for $2.4 billion, gaining access to ipilimumab (Yervoy) and other immuno-oncology assets. This marked a pivotal shift toward oncology and immunoscience. Over the subsequent decade, BMS achieved significant success with drugs like Eliquis (apixaban), Opdivo (nivolumab), and Orencia (abatacept), with these products generating billions in annual revenue. The strategic restructuring proved successful, culminating in the $74 billion acquisition of Celgene in 2019, though this led to additional job cuts as part of integration efforts.

**Entremed**: The company's situation after the 2008 layoffs remained challenging. Entremed continued to struggle with developing its lead compound, panzem (2-methoxyestradiol), for various cancers. In 2010, the company initiated a 1-for-6 reverse stock split to maintain NASDAQ listing compliance. By 2013, Entremed underwent a reverse merger with SunTrust Acquisition Corp., effectively a corporate shell acquisition, and eventually transitioned its focus. The company's anti-angiogenesis approach, while scientifically interesting, faced difficulties competing with more successful angiogenesis inhibitors like bevacizumab (Avastin), which had established clinical utility.

**Industry Context**: The 2008-2012 period represented a challenging era for pharmaceutical research, with major companies closing research facilities and reducing chemistry-focused positions. However, this restructuring coincided with the industry's shift toward biologics, with monoclonal antibodies and other large-molecule drugs becoming increasingly important therapeutic modalities. Many chemists found their skills less directly applicable to biologics development, contributing to the career challenges mentioned in the original article.

## 3. PREDICTIONS

* **"More of a perennial than anyone would like"** (regarding pharma layoffs continuing): This turned out to be accurate. The pharmaceutical industry continued experiencing waves of layoffs and restructuring throughout the 2010s, driven by patent cliffs, merger integrations, and strategic pivots toward biologics and specialty medicines. Notable examples include Pfizer's ongoing restructuring, AstraZeneca's research site closures, and various companies reducing their cardiovascular/metabolic disease research.

The article's underlying concern about the precarious nature of pharmaceutical research careers proved prescient, as the industry fundamentally restructured away from traditional small-molecule discovery toward biologics, precision medicine, and external innovation models, leading to reduced internal research infrastructure and continued employment volatility.

## 4. INTEREST

Rating: **6/10**

The article captures an important transitional moment in pharmaceutical industry history, documenting the human impact of strategic restructuring and the challenges faced by research scientists during a period of significant industry transformation. While not highly technical or scientifically groundbreaking, it provides valuable historical context about the difficulties faced by the sector and individual researchers during this time.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20081216-layoffs-more-layoffs.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_